|
1）Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23: 1631-4
|
|
|
|
2）Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 Suppl 2: ii1-47
|
|
|
|
|
|
3）Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005; 16: 3403-10
|
|
|
|
|
|
4）Obara N, Suzuki N, Kim K, et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008; 111: 5223-32
|
|
|
|
|
|
5）Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011; 121: 3981-90
|
|
|
|
|
|
6）Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013; 27: 41-53
|
|
|
|
|
|
7）Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012; 318: 1068-73
|
|
|
|
|
|
8）Tanaka T, Yamaguchi J, Higashijima Y, et al. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. FASEB J. 2013; 27: 4059-75
|
|
|
|
|
|
9）Chiang CK, Tanaka T, Inagi R, et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011; 91: 1564-71
|
|
|
|
|
|
10）Chiang CK, Nangaku M, Tanaka T, et al. Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. Am J Physiol Cell Physiol. 2013; 304: C342-53
|
|
|
|
|
|
11）Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012; 59: 108-16
|
|
|
|
|
|
12）Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74: 791-8
|
|
|
|
|
|
13）Badve SV, Beller EM, Cass A, et al. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev. 2013; 8: CD006861
|
|
|
|
|
|
14）Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002; 17 Suppl 11: 39-43
|
|
|
|
|
|
15）Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1077-83
|
|
|
|
|
|
16）Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363: 1146-55
|
|
|
|
|
|
17）López-Gómez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008: S75-81
|
|
|
|
|
|
18）Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011; 26: 2641-8
|
|
|
|
|
|
19）Majoni SW, Ellis JA, Hall H, et al. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Hemodial Int. 2014. [Epub ahead of print]
|
|
|
|
|
|
20）Cooper AC, Mikhail A, Lethbridge MW, et al. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol. 2003; 14: 1776-84
|
|
|
|
|
|
21）Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010; 55: 726-41
|
|
|
|
|
|
22）Vos FE, Schollum JB, Coulter CV, et al. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011; 58: 591-8
|
|
|
|
|
|
23）Rossert J, Gassmann-Mayer C, Frei D, et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007; 22: 794-800
|
|
|
|
|
|
24）Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 991-8
|
|
|
|
|
|
25）椿原美治, 西 慎一, 秋葉 隆, 他. 2008年版 日本透析医学会. 慢性腎臓病患者における腎性貧血治療のガイドライン. 日本透析医学会雑誌. 2008; 41: 661-716
|
|
|
|
|
26）Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102: 783-8
|
|
|
|
|
|
27）Loreal O, Cavey T, Bardou-Jacquet E, et al. Iron, hepcidin, and the metal connection. Front Pharmacol. 2014; 5: 128
|
|
|
|
|
|
28）Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010; 31: 534-40
|
|
|
|
|
|
29）中井 滋, 花房規男, 政金生人, 他. わが国の慢性透析療法の現況（2012年12月31日現在）. 日本透析医学会雑誌. 2014; 47: 1-56
|
|
|
|
|
30）Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009; 4: 57-61
|
|
|
|
|
|
31）Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361: 2436-48
|
|
|
|
|
|
32）Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013; 165: 575-82. e3
|
|
|
|
|
|
33）Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl (2011). 2012; 2: 292-8
|
|
|
|
|
|
34）Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013; 347: f4822
|
|
|
|
|
|
35）Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014; 86: 845-54
|
|
|
|
|